Peter Lockwood

821 total citations
23 papers, 556 citations indexed

About

Peter Lockwood is a scholar working on Molecular Biology, Pharmacology and Economics and Econometrics. According to data from OpenAlex, Peter Lockwood has authored 23 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Pharmacology and 5 papers in Economics and Econometrics. Recurrent topics in Peter Lockwood's work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Statistical Methods in Clinical Trials (5 papers) and bioluminescence and chemiluminescence research (3 papers). Peter Lockwood is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (5 papers), Statistical Methods in Clinical Trials (5 papers) and bioluminescence and chemiluminescence research (3 papers). Peter Lockwood collaborates with scholars based in United States, Canada and Belgium. Peter Lockwood's co-authors include Karl R. Kopecky, Wayne Ewy, John G. Clement, Cedric Mumford, Paul M. Lundy, Robert Frew, David Hermann, Ayman El‐Kattan, Brian Corrigan and Jack Cook and has published in prestigious journals such as Anesthesiology, Life Sciences and Pharmaceutical Research.

In The Last Decade

Peter Lockwood

23 papers receiving 525 citations

Peers

Peter Lockwood
V.G. Casabó Spain
J.‐M. POIRIER France
James A. Oppermann United States
Linyee Shum United States
Check Y. Quon United States
Louis Leung United States
Susanna Tse United States
Haiyung Cheng United States
Keith K. H. Chan United States
H Jaeger Germany
V.G. Casabó Spain
Peter Lockwood
Citations per year, relative to Peter Lockwood Peter Lockwood (= 1×) peers V.G. Casabó

Countries citing papers authored by Peter Lockwood

Since Specialization
Citations

This map shows the geographic impact of Peter Lockwood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Lockwood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Lockwood more than expected).

Fields of papers citing papers by Peter Lockwood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Lockwood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Lockwood. The network helps show where Peter Lockwood may publish in the future.

Co-authorship network of co-authors of Peter Lockwood

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Lockwood. A scholar is included among the top collaborators of Peter Lockwood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Lockwood. Peter Lockwood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sawant‐Basak, Aarti, Laigao Chen, Peter Lockwood, et al.. (2023). Investigating CNS distribution of PF‐05212377, a P‐glycoprotein substrate, by translation of 5‐HT6 receptor occupancy from non‐human primates to humans. Biopharmaceutics & Drug Disposition. 44(1). 48–59. 2 indexed citations
2.
Lockwood, Peter, Vu Le, Melissa O’Gorman, et al.. (2020). The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers. Clinical Pharmacology in Drug Development. 9(7). 849–854. 37 indexed citations
3.
Sawant‐Basak, Aarti, R. Scott Obach, Angela C. Doran, et al.. (2018). Metabolism of a 5HT6 Antagonist, 2-Methyl-1-(Phenylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzo[d]imidazole (SAM-760): Impact of Sulfonamide Metabolism on Diminution of a Ketoconazole-Mediated Clinical Drug-Drug Interaction. Drug Metabolism and Disposition. 46(7). 934–942. 6 indexed citations
4.
Fullerton, Terence, Brendon Binneman, William David, et al.. (2018). A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil. Alzheimer s Research & Therapy. 10(1). 38–38. 27 indexed citations
5.
Tafazzoli, Ali, et al.. (2018). The Economic Impact of New Therapeutic Interventions on Neuropsychiatric Inventory (NPI) Symptom Scores in Patients with Alzheimer Disease. Dementia and Geriatric Cognitive Disorders Extra. 8(1). 158–173. 4 indexed citations
6.
Lockwood, Peter, L. Pauer, Joseph M. Scavone, et al.. (2016). The Pharmacokinetics of Pregabalin in Breast Milk, Plasma, and Urine of Healthy Postpartum Women. Journal of Human Lactation. 32(3). NP1–NP8. 15 indexed citations
7.
Fullerton, Terence, Brendon Binneman, William David, et al.. (2016). P1‐047: A Phase 2 Clinical Trial of PF‐05212377 (SAM‐760) in Subjects with Mild to Moderate Alzheimer's Disease with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil. Alzheimer s & Dementia. 12(7S_Part_8). 1 indexed citations
8.
Ueckert, Sebastian, et al.. (2015). Modeling the Neuropsychiatric Inventory (NPI) - Strengths and Weaknesses of a Multidimensional Item Response Theory Approach. Journal of Pharmacokinetics and Pharmacodynamics. 42. 1 indexed citations
9.
Feng, Bo, Susan Hurst, Yasong Lu, et al.. (2013). Quantitative Prediction of Renal Transporter-Mediated Clinical Drug–Drug Interactions. Molecular Pharmaceutics. 10(11). 4207–4215. 29 indexed citations
10.
Rogers, James A., Peter Lockwood, Y. Brault, et al.. (2012). P3‐367: Model‐based analysis to support strategic decision‐making: A case study from the development of a 5HT6 antagonist for the treatment of Alzheimer's disease. Alzheimer s & Dementia. 8(4S_Part_16). 1 indexed citations
11.
Grice, Jeffrey E., Susan Ciotti, Norman Weiner, et al.. (2009). Relative uptake of minoxidil into appendages and stratum corneum and permeation through human skin in vitro. Journal of Pharmaceutical Sciences. 99(2). 712–718. 40 indexed citations
12.
Lockwood, Peter, Wayne Ewy, David Hermann, & Nicholas H. G. Holford. (2006). Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease. Pharmaceutical Research. 23(9). 2050–2059. 28 indexed citations
13.
Miller, Raymond, Wayne Ewy, Brian Corrigan, et al.. (2005). How Modeling and Simulation Have Enhanced Decision Making in New Drug Development. Journal of Pharmacokinetics and Pharmacodynamics. 32(2). 185–197. 99 indexed citations
14.
Lockwood, Peter, Jack Cook, Wayne Ewy, & Jaap W. Mandema. (2003). The Use of Clinical Trial Simulation to Support Dose Selection: Application to Development of a New Treatment for Chronic Neuropathic Pain. Pharmaceutical Research. 20(11). 1752–1759. 32 indexed citations
15.
Lockwood, Peter, et al.. (2000). Computer assisted trial design to support dose selection for CI-1017 in phase 2 Alzheimers studies. Neurobiology of Aging. 21. 168–168. 2 indexed citations
16.
Tucker, Gordon C. & Peter Lockwood. (2000). Circaea alpina L.. 1 indexed citations
17.
Lundy, Paul M., et al.. (1986). Differential Effects of Ketamine Isomers on Neuronal and Extraneuronal Catecholamine Uptake Mechanisms. Anesthesiology. 64(3). 359–363. 60 indexed citations
18.
19.
Kopecky, Karl R., et al.. (1975). Preparation and Thermolysis of Some 1,2-Dioxetanes. Canadian Journal of Chemistry. 53(8). 1103–1122. 97 indexed citations
20.
Kopecky, Karl R., et al.. (1973). 4-Methyl-3,3-pentamethylene-1,2-dioxetane. Lack of its Formation in Ozonation of Ethylidenecyclohexane in Pinacolone. Canadian Journal of Chemistry. 51(3). 468–470. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by V.G. Casabó Breakdown of academic impact, for papers by J.‐M. POIRIER Breakdown of academic impact, for papers by James A. Oppermann Breakdown of academic impact, for papers by Linyee Shum Breakdown of academic impact, for papers by Check Y. Quon Breakdown of academic impact, for papers by Louis Leung Breakdown of academic impact, for papers by Susanna Tse Breakdown of academic impact, for papers by Haiyung Cheng Breakdown of academic impact, for papers by Keith K. H. Chan Breakdown of academic impact, for papers by H Jaeger
Rankless by CCL
2026